Plasma Metabolome Signature Indicative of Germline Status Independent of Cancer Incidence.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Penkert, JudithMärtens, Andre
Seifert, Martin
Auber, Bernd
Derlin, Katja
Hille-Betz, Ursula
Hörmann, Philipp
Klopp, Norman
Prokein, Jana
Schlicker, Lisa
Wacker, Frank
Wallaschek, Hannah
Schlegelberger, Brigitte
Hiller, Karsten
Ripperger, Tim
Illig, Thomas
Issue Date
2021-04-07
Metadata
Show full item recordAbstract
Individuals carrying a pathogenic germline variant in the breast cancer predisposition gene BRCA1 (gBRCA1+) are prone to developing breast cancer. Apart from its well-known role in DNA repair, BRCA1 has been shown to powerfully impact cellular metabolism. While, in general, metabolic reprogramming was named a hallmark of cancer, disrupted metabolism has also been suggested to drive cancer cell evolution and malignant transformation by critically altering microenvironmental tissue integrity. Systemic metabolic effects induced by germline variants in cancer predisposition genes have been demonstrated before. Whether or not systemic metabolic alterations exist in gBRCA1+ individuals independent of cancer incidence has not been investigated yet. We therefore profiled the plasma metabolome of 72 gBRCA1+ women and 72 age-matched female controls, none of whom (carriers and non-carriers) had a prior cancer diagnosis and all of whom were cancer-free during the follow-up period. We detected one single metabolite, pyruvate, and two metabolite ratios involving pyruvate, lactate, and a metabolite of yet unknown structure, significantly altered between the two cohorts. A machine learning signature of metabolite ratios was able to correctly distinguish between gBRCA1+ and controls in ~82%. The results of this study point to innate systemic metabolic differences in gBRCA1+ women independent of cancer incidence and raise the question as to whether or not constitutional alterations in energy metabolism may be involved in the etiology of BRCA1-associated breast cancer.Citation
Front Oncol. 2021 Apr 7;11:627217. doi: 10.3389/fonc.2021.627217.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
FrontiersJournal
Frontiers in oncologyPubMed ID
33898308Type
ArticleLanguage
enISSN
2234-943Xae974a485f413a2113503eed53cd6c53
10.3389/fonc.2021.627217
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers.
- Authors: Cuyàs E, Fernández-Arroyo S, Alarcón T, Lupu R, Joven J, Menendez JA
- Issue date: 2016 Aug 16
- Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience.
- Authors: Hur JY, Kim JY, Ahn JS, Im YH, Lee J, Kwon M, Park YH
- Issue date: 2020 May 21
- Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients.
- Authors: Fan Z, Hu L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu Y, Xie Y
- Issue date: 2019 Oct
- Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.
- Authors: Yoshihara K, Enomoto T, Aoki D, Watanabe Y, Kigawa J, Takeshima N, Inomata H, Hattori K, Jinushi M, Tsuda H, Sugiyama T
- Issue date: 2020 Sep
- Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
- Authors: Moya-Alarcón C, González-Domínguez A, Simon S, Pérez-Román I, González-Martín A, Bayo-Lozano E, Sánchez-Heras AB
- Issue date: 2019 Aug